JP Morgan Maintains Overweight on Enanta Pharmaceuticals, Lowers Price Target to $17

Benzinga · 23h ago
JP Morgan analyst Anupam Rama maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Overweight and lowers the price target from $19 to $17.